This recombinant human Cardiotrophin-like cytokine factor 1 (CLCF1) is a semi-custom product. There are 5 expression system options: Yeast, E. coli, In Vivo Biotinylation in E. coli, Baculovirus, and Mammalian cell. Your requirements will be given top priority in determining the protein tags. For proteins within 800 aa, risk-free custom service is guaranteed. It means you will not be charged if the protein cannot be delivered.
CLCF1 is a member of the IL-6 family of cytokines [1][5]. CLCF regulates the acute-phase response to injury and infection [2]. CLCF1 has been identified as a potential circulating permeability factor in the development of primary focal segmental glomerulosclerosis (FSGS) [3]. It forms a heterodimer complex with cytokine receptor-like factor 1 (CRLF1) [4].
The signaling of CLCF1 occurs through the gp130/Jak/STAT pathway, which is a common pathway for cytokines like IL-6, IL-11, LIF, OSM, and CNTF [6]. The LIF receptor β and gp130 complex is the receptor for CLCF1 and is also shared by other related cytokines [7]. CLCF1 is associated with various conditions, including Crisponi/cold-induced sweating syndrome (CS/CISS) [8]. Studies have shown that CLCF1 plays a role in promoting glioblastoma and is considered an unfavorable prognostic biomarker [4].
References:
[1] S. Jones and B. Jenkins, Recent insights into targeting the il-6 cytokine family in inflammatory diseases and cancer, Nature Reviews Immunology, vol. 18, no. 12, p. 773-789, 2018. https://doi.org/10.1038/s41577-018-0066-7
[2] P. Heinrich, I. Behrmann, S. Haan, H. Hermanns, G. Müller‐Newen, & F. Schaper, Principles of interleukin (il)-6-type cytokine signalling and its regulation, Biochemical Journal, vol. 374, no. 1, p. 1-20, 2003. https://doi.org/10.1042/bj20030407
[3] J. Tumlin, Protecting podocytes: a key target for therapy of focal segmental glomerulosclerosis, American Journal of Nephrology, vol. 47, no. Suppl. 1, p. 14-29, 2018. https://doi.org/10.1159/000481634
[4] S. Shen, J. Guo, J. Huang, Q. Zhang, & Y. Cui, Bromodomain-containing protein 4 activates cardiotrophin-like cytokine factor 1, an unfavorable prognostic biomarker, and promotes glioblastoma in vitro, Annals of Translational Medicine, vol. 10, no. 8, p. 475-475, 2022. https://doi.org/10.21037/atm-22-1164
[5] V. Peev and E. Hahm, Unwinding focal segmental glomerulosclerosis, F1000research, vol. 6, p. 466, 2017. https://doi.org/10.12688/f1000research.10510.1
[6] P. Heinrich, I. Behrmann, G. Müller‐Newen, F. Schaper, & L. Graeve, Interleukin-6-type cytokine signalling through the gp130/jak/stat pathway, Biochemical Journal, vol. 334, no. 2, p. 297-314, 1998. https://doi.org/10.1042/bj3340297
[7] N. Nicola and J. Babon, Leukemia inhibitory factor (lif), Cytokine & Growth Factor Reviews, vol. 26, no. 5, p. 533-544, 2015. https://doi.org/10.1016/j.cytogfr.2015.07.001
[8] L. Crisponi, I. Buers, & F. Rutsch, Crlf1 and clcf1 in development, health and disease, International Journal of Molecular Sciences, vol. 23, no. 2, p. 992, 2022. https://doi.org/10.3390/ijms23020992
